A number of firms (COGLA, Phylaxia Vet. Bio. Co) and researchers in the history of the Ceva Group have made their name by their veterinary research work, notably in the biological field.

For example, renowned scientists such as Aladar AUJEZSKY or Adorjan BARTHA have worked for Hungarian firm Phylaxia Vet Bio Co (today CEVA PHYLAXIA).
This scientific excellence has always been an integral part of the Group’s culture, developing adapted responses to the main infectious diseases affecting swine rearing today:

  • Classical swine fever: COGLAPEST® is an attenuated live vaccine with a coloured indicator allowing monitoring of vaccine efficacy.
  • Respiratory diseases (Actinobacillus pleuropneumoniae): COGLAPIX® The only vaccine based on bacterial toxoids, providing the best protection against all the serotypes of APP and minimal post-vaccination reactions at one and the same time.
  • Clostridiosis: COGLAMUNE® has the highest titre in α and ß toxoids to prevent neonatal diarrhoea in piglets, necrotic enteritis or enterotoxaemia.
  • Aujeszky disease: the AUPHYL Plus® (attenuated live) vaccine offers antibody-related and cell-mediated immunity. Its "deleted" strain allows serological differentiation between vaccinated animals and those actually infected by the virus. Other killed vaccines (AUJESPIG®) complete the Group’s comprehensive offering.

From one country to another, product lines are adapted to local demand and regulatory requirements. For further information, please take a look at the CEVA Santé Animale site for your country. Warning: the information provided on the products depends on national registrations. Access to technical information is restricted to authorised persons.

Back to top